Average Co-Inventor Count = 9.29
ph-index = 14
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Forma Therapeutics, Inc. (35 from 125 patents)
2. Valo Health, Inc. (13 from 29 patents)
3. Genentech, Inc. (7 from 3,221 patents)
4. Neurogen Corporation (7 from 305 patents)
5. Forma Tm, LLC (7 from 10 patents)
6. Valo Early Discovery, Inc. (6 from 15 patents)
7. Novo Nordisk Healthcare Ag (3 from 88 patents)
8. Other (2 from 832,680 patents)
9. H. Lee Moffitt Cancer Center and Research Institute, Inc. (1 from 290 patents)
10. Novartis International Pharmaceutical, Ltd. (1 from 29 patents)
74 patents:
1. 12336981 - Compounds and compositions for the inhibition of NAMPT
2. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
3. 12071440 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
4. 12053458 - Treating sickle cell disease with a pyruvate kinase R activating compound
5. 11980611 - Treating sickle cell disease with a pyruvate kinase R activating compound
6. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
7. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
8. 11649242 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
9. 11547701 - Compounds and compositions for the inhibition of NAMPT
10. 11535607 - Isoindolines as HDAC inhibitors
11. 11479564 - Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
12. 11414392 - [6,6] fused bicyclic HDAC8 inhibitors
13. 11345672 - Methods using HDAC11 inhibitors
14. 11279681 - 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
15. 11279687 - Compounds and compositions for the inhibition of NAMPT